


## PRODUCT DATA SHEET

**Product:** Herbimycin A

**Cat. No.:** KT-375 (1 mg)

Page 1 of 2



**Formula:**

$C_{30}H_{42}N_2O_9$

**Molecular Weight:**

574

**Description:**

Herbimycin A is a microbial metabolite that was first identified as a herbicidal compound and has also been found to have anti-Tobacco Mosaic Virus (TMV) and anti-tumor activity. Herbimycin A is the first antibiotic which inhibits src oncogene function. Herbimycin A shows morphology-normalizing activity in tumor cells, and also has anti-angiogenesis activity.

**Format:**

Herbimycin A is supplied in lyophilized form.

**Production:**

Isolated from cultures of *Streptomyces hygroscopicus* strain AM-3672.

**Purity:**

>90% by HPLC

**Solubility:**

Dissolve in 1 mL DMSO. Dilute just prior to use in methanol or ethanol.


**Storage:**

Store DMSO stock solution at 4°C. Store lyophilized form at -20°C long term.

**References:**

1. Omura, S. et al. (1979). Herbimycin, a new antibiotic produced by a strain of *Streptomyces*. *J. Antibiot.* 32: 255-61.

2. Omura, S. et al. (1979). Structure of Herbimycin, a new ansamycin antibiotic. *Tetrahed. Lett.* 44: 4323-26.
3. Iwai, Y. et al. (1980). Herbimycin B, a new benzoquinonoid ansamycin with anti-TMV and herbicidal activities. *J. Antibiot.* 33: 1114-9.
4. Duros, J. and Suffness, M. (1981). New antitumor substances of natural origin. *Cancer Treat. Rev.* 8: 63-87.
5. Omura, S. et al. (1984). Chemical modification and antitumor activity of herbimycin A. 8,9-epoxide, 7,9-cyclic carbonate and 17 or 19-amino derivatives. *J. Antibiot.* 37: 1264-7.
6. Uehara, Y. et al. (1985). Screening of agents which convert "transformation morphology" of Rous sarcoma virus-infected rat kidney cells to "normal morphology". *Jpn. J. Cancer Res.* 76: 672-5.
7. Shibata, K. et al. (1986). Chemical modification of herbimycin A, synthesis and in vivo antitumor activities of halogenated and other related derivatives of herbimycin A. *J. Antibiot.* 39: 415-23.
8. Uehara, K. et al. (1986). Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. *Mol. Cell. Biol.* 6: 2198-206.
9. Shiba, Y. et al. (1987). Suppression by Herbimycin A of 12-O-tetradecanoylphorbol-13-acetate-induced dissociation of cells and morphological changes in cultured FL and MDCK cells. *Jpn. J. Cancer Res.* 78: 1216-23.
10. Umezawa, K. et al. (1987). Enhancement of fibronectin expression by herbimycin A. *Experientia* 43: 614-6.
11. Murakami, Y. et al. (1988). Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts. *Cancer Res.* 48 (6): 1587-90.
12. Uehara, Y. et al. (1988). Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. *Virology* 164: 294-8.
13. Honma, Y. et al. (1989). Induction of erythroid differentiation of K562 human leukemic cells by Herbimycin A, an inhibitor of tyrosine kinase activity. *Cancer Res.* 49: 331-34.



## PRODUCT DATA SHEET

Cat. No.: KT-375

Page 2 of 2

14. Oikawa, T. et al. (1989). Powerful antiangiogenic activity of Herbimycin A (named angiostatic antibiotic). *J. Antibiotics* 42: 1202-204.
15. Uehara, Y. et al. (1989). Mechanism of reversion of Rous sarcoma virus transformation by Herbimycin A: Reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src. *Cancer Res.* 49: 780-85.
16. Uehara, Y. et al. (1989). Irreversible inhibition of v-src tyrosine kinase activity by Herbimycin A and its abrogation by sulfhydryl compounds. *Biochem. Biophys. Res. Commun.* 163: 803-809.
17. Yamashita, T. et al. (1989). A new activity of Herbimycin A: inhibition of angiogenesis. *J. Antibiotics* 42: 1015-16.
18. Fukazawa, H. et al. (1990). Effects of Herbimycin A and various SH-reagents on p60v-src kinase activity in vitro. *Biochem. Biophys. Res. Commun.* 173 (1): 276-82.
19. Fukazawa, H. et al. (1991). Specific inhibition of cytoplasmic protein tyrosine kinases by Herbimycin A in vitro. *Biochem. Pharmacol.* 42 (9): 1661-71.
20. Graber, M. et al. (1992). The protein kinase inhibitor Herbimycin A, but not genistein, specifically inhibits signal transduction by the T cell antigen receptor. *Int. Immunol.* 4 (11): 1201-10.
21. Iwasaki, T. et al. (1992). Herbimycin A blocks IL-1-induced NF-kappa B DNA-binding activity in lymphoid cell lines. *FEBS Lett.* 298 (2-3): 240-44.
22. Satoh, T. et al. (1992). Inhibition of interleukin 3 and granulocyte-macrophage colony-stimulating factor stimulated increase of active ras-GTP by Herbimycin A, a specific inhibitor of tyrosine kinases. *J. Biol. Chem.* 267 (4): 2537-41.
23. Hamaguchi, M. et al. (1993). Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3'kinase. *Oncogene* 8 (3): 559-64.
24. Yoneda, T. et al. (1993). Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. *J. Clin. Invest.* 91 (6): 2791-95.
25. Honma, Y. (1994). Acycloguanosine and Herbimycin A co-operatively inhibit proliferation and induce erythrodifferentiation of human myeloid leukemia K562 cells. *Leuk. Res.* 18 (11): 851-854.
26. Kruse, H.J. et al. (1994). Thrombin-induced  $Ca^{2+}$  influx and protein tyrosine phosphorylation in endothelial cells is inhibited by Herbimycin A. *Biochem. Biophys. Res. Commun.* 202 (3): 1651-56.
27. Lee, E. et al. (1994). Selective inhibition of dexamethasone-induced apoptosis in rat thymocytes by Herbimycin A. *Biochem. Biophys. Res. Commun.* 202 (1): 128-34.
28. Hegde, R.S. et al. (1995). Short circuiting stress protein expression via a tyrosine kinase inhibitor, Herbimycin A. *J. Cell Physiol.* 165 (1): 186-200.
29. Mahon, T.M. et al. (1995). Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kB activation in T lymphocytes. *J. Biol. Chem.* 270 (48): 28557-64.
30. Murate, T. et al. (1995). Herbimycin A inhibits phorbol ester-induced morphologic changes, adhesion, and megakaryocytic differentiation of the leukemia cell line, MEG-01. *Proc. Soc. Exp. Biol. Med.* 209 (3): 270-78.
31. Sepp-Lorenzino, L. et al. (1995). Herbimycin A induces the 20 S proteasome-and ubiquitin-dependent degradation of receptor tyrosine kinases. *J. Biol. Chem.* 270 (28): 16580-7.
32. Tetsuka, T. et al. (1996). Tyrosine kinase inhibitors, genistein and herbimycin A, do not block interleukin-1 beta-induced activation of NF-kappa B in rat mesangial cells. *Biochem. Biophys. Res. Commun.* 218 (3): 808-12.

### Limitations:

For *in vitro* research use only. Not for use in diagnostics or in humans.

### Warranty:

No warranties, expressed or implied, are made regarding the use of this product. KAMIYA BIOMEDICAL COMPANY is not liable for any damage, personal injury, or economic loss caused by this product.